{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:52:10Z","timestamp":1761897130400,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clml.2019.09.607","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T01:53:01Z","timestamp":1569894781000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic Impact of ABO Blood Group on Survival in Patients With Malignant Lymphoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Yuki","family":"Osada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Nishiyama-Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Aisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.clml.2019.09.607_bib1","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.09.607_bib2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.607_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/1471-2407-12-319","article-title":"ABO blood group and prognosis in patients with pancreatic cancer","volume":"12","author":"Rahbari","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2019.09.607_bib4","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1007\/s13277-014-1960-7","article-title":"The ABO blood group predicts survival in esophageal squamous cell carcinoma in patients who ever smoked: a retrospective study from China","volume":"35","author":"Sun","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.clml.2019.09.607_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/bjc.2014.302","article-title":"Prognostic value of ABO blood group in patients with surgically resected colon cancer","volume":"111","author":"Cao","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2019.09.607_bib6","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1038\/bjc.2013.559","article-title":"Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma","volume":"109","author":"Ouyang","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2019.09.607_bib7","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.7314\/APJCP.2014.15.9.4055","article-title":"Significance of ABO-Rh blood groups in response and prognosis in breast cancer patients treated with radiotherapy and chemotherapy","volume":"15","author":"Cihan","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2019.09.607_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.09.607_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.seminhematol.2004.01.001","article-title":"Red blood cell blood group antigens: structure and function","volume":"41","author":"Reid","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2019.09.607_bib10","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1073\/pnas.87.17.6674","article-title":"Molecular cloning, sequence, and expression of human GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA that can form the H blood group antigen","volume":"87","author":"Larsen","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.09.607_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1537-2995.1990.30891020320.x","article-title":"Cloning the ABH genes","volume":"30","author":"Yamamoto","year":"1990","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2019.09.607_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ijc.25339","article-title":"ABO blood group and incidence of epithelial ovarian cancer","volume":"128","author":"Gates","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2019.09.607_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jnci\/djp020","article-title":"ABO blood group and the risk of pancreatic cancer","volume":"101","author":"Wolpin","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.09.607_bib14","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.25426","article-title":"Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case control study","volume":"128","author":"Ben","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2019.09.607_bib15","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/bmj.310.6995.1639","article-title":"ABO and Rh blood groups in patients with cholelithiasis and carcinoma of the gall bladder","volume":"310","author":"Pandey","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2019.09.607_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0304-4165(99)00183-X","article-title":"Antigen structure and genetic basis of histoblood groups A, B and O: their changes associated with human cancer","volume":"1473","author":"Hakomori","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2019.09.607_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0463.2001.tb00011.x","article-title":"ABH and Lewis histo-blood group antigens in cancer","volume":"109","author":"Le Pendu","year":"2001","journal-title":"APMIS"},{"key":"10.1016\/j.clml.2019.09.607_bib18","doi-asserted-by":"crossref","first-page":"19257","DOI":"10.1016\/S0021-9258(17)30652-X","article-title":"Sugar-nucleotide donor specificity of histo-blood group A and B transferases is based on amino acid substitutions","volume":"265","author":"Yamamoto","year":"1990","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.09.607_bib19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00441-014-1851-7","article-title":"Endothelial cadherins in cancer","volume":"355","author":"Breier","year":"2014","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.clml.2019.09.607_bib20","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.cellsig.2014.07.011","article-title":"Regulation of alternative splicing of CD44 in cancer","volume":"26","author":"Prochazka","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.clml.2019.09.607_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogenety of epidermal growth factor receptor signaling networks in glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2019.09.607_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40880-017-0229-0","article-title":"Prognostic role of ABO blood type in patients with extranodal natural killer\/T cell lymphoma, nasal type: a triple center study","volume":"36","author":"Li","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.clml.2019.09.607_bib23","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1538-7836.2007.02579.x","article-title":"ABO blood group, other risk factors and incidence of various thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)","volume":"5","author":"Ohira","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.clml.2019.09.607_bib24","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/MPH.0000000000000333","article-title":"ABO group as a thrombotic risk factor in children with acute lymphoblastic leukemia: a retrospective study of 523 patients","volume":"37","author":"Mizrahi","year":"2015","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2019.09.607_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1559-0275-8-7","article-title":"Aberrant glycosylation associated with enzymes as cancer biomarkers","volume":"8","author":"Meany","year":"2011","journal-title":"Clin Proteom"},{"key":"10.1016\/j.clml.2019.09.607_bib26","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/hmg\/ddq061","article-title":"Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels","volume":"19","author":"Barbalic","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clml.2019.09.607_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.607_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/10428194.2012.691482","article-title":"Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi\/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study","volume":"54","author":"Carella","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.09.607_bib29","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019319949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019319949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:06Z","timestamp":1761870906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019319949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2152265019319949"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.607","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Impact of ABO Blood Group on Survival in Patients With Malignant Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}